Patents by Inventor Tetsu Kawano
Tetsu Kawano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200341014Abstract: The present invention provides a method for evaluating the pharmacological action of HGF that utilizes a PD marker in which fluctuation is recognized by administration of hepatocyte growth factor (HGF) in a broader range of subjects. A method for evaluating the pharmacodynamic action of HGF is provided. The aforementioned evaluation method is characterized in that it comprises a step of measuring the ApoA4 level in a biological sample collected from a test subject who was administered HGF. According to the present invention, a kit for evaluating the pharmacodynamic action of HGF comprising an anti-ApoA4 antibody is further provided.Type: ApplicationFiled: March 16, 2017Publication date: October 29, 2020Inventors: Mai Kimura, Sotaro Motoi, Takashi Obara, Katsuhiro Moriya, Hideaki Ogasawara, Yoshihisa Arita, Tetsu Kawano
-
Patent number: 9809647Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: GrantFiled: August 3, 2015Date of Patent: November 7, 2017Assignee: Eisai R&D Management Co., Ltd.Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Patent number: 9371389Abstract: An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of SEQ ID NO: 91.Type: GrantFiled: August 30, 2012Date of Patent: June 21, 2016Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Miyuki Nishimura, Tetsu Kawano, Yukihisa Sawa, Toshio Imai
-
Publication number: 20160046707Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: ApplicationFiled: August 3, 2015Publication date: February 18, 2016Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Patent number: 9133273Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: GrantFiled: June 21, 2013Date of Patent: September 15, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Patent number: 8932592Abstract: The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.Type: GrantFiled: October 28, 2010Date of Patent: January 13, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Miyuki Nishimura, Yoshimasa Sakamoto, Tetsu Kawano, Toshio Imai
-
Publication number: 20140193421Abstract: An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of SEQ ID NO: 91.Type: ApplicationFiled: August 30, 2012Publication date: July 10, 2014Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yoshimasa Sakamoto, Miyuki Nishimura, Tetsu Kawano, Yukihisa Sawa, Toshio Imai
-
Publication number: 20140045215Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: ApplicationFiled: June 21, 2013Publication date: February 13, 2014Inventors: Toshio Imai, Brad Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Patent number: 8491901Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: GrantFiled: November 18, 2011Date of Patent: July 23, 2013Inventors: Toshio Imai, Brad Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Publication number: 20120213799Abstract: The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.Type: ApplicationFiled: October 28, 2010Publication date: August 23, 2012Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Miyuki Nishimura, Yoshimasa Sakamoto, Tetsu Kawano, Toshio Imai
-
Publication number: 20120148592Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: ApplicationFiled: November 18, 2011Publication date: June 14, 2012Inventors: Toshio Imai, Brad Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Publication number: 20100279978Abstract: The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist.Type: ApplicationFiled: May 7, 2010Publication date: November 4, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Tetsu Kawano, Seiichi Kobayashi, Minghuang Zhang, Hiroshi Shirota
-
Patent number: 7727974Abstract: The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist.Type: GrantFiled: May 15, 2006Date of Patent: June 1, 2010Assignee: Eisai R & D Management Co., Ltd.Inventors: Tetsu Kawano, Seiichi Kobayashi, Minghuang Zhang, Hiroshi Shirota
-
Publication number: 20070122845Abstract: The present invention provides methods for identifying a GPR83 agonist capable of stimulating a regulatory T cell function and methods for identifying a GPR83 antagonist capable of suppressing a regulatory T cell function.Type: ApplicationFiled: September 15, 2006Publication date: May 31, 2007Applicant: Eisai R&D Management Co., Ltd.Inventors: Tetsu Kawano, Junro Kuromitsu, Akiko Hamaguchi, Keiko Yamaguchi, Takashi Seiki, Kazuma Takase
-
Publication number: 20070072824Abstract: The invention provides methods of reducing the severity of mucositis, involving administration of a toll-like receptor 4 antagonist.Type: ApplicationFiled: May 15, 2006Publication date: March 29, 2007Applicant: Eisai Co., Ltd.Inventors: Tetsu Kawano, Seiichi Kobayashi, Minghuang Zhang, Hiroshi Shirota
-
Patent number: 6747010Abstract: An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.Type: GrantFiled: January 2, 2003Date of Patent: June 8, 2004Assignee: Kirin Beer Kabushiki KaishaInventors: Masaru Taniguchi, Tetsu Kawano, Yasuhiko Koezuka
-
Publication number: 20030139351Abstract: An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.Type: ApplicationFiled: January 2, 2003Publication date: July 24, 2003Applicant: KIRIN BEER KABUSHIKI KAISHAInventors: Masaru Taniguchi, Tetsu Kawano, Yasuhiko Koezuka
-
Patent number: 6531453Abstract: An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.Type: GrantFiled: October 12, 1999Date of Patent: March 11, 2003Assignee: Kirin Beera Kabushiki KaishaInventors: Masaru Taniguchi, Tetsu Kawano, Yasuhiko Koezuka